PT  - JOURNAL ARTICLE
AU  - Magadmi, Rania
AU  - Nassibi, Sara
AU  - Kamel, Fatemah
AU  - Al-Rafiah, Aziza R.
AU  - Bakhshwin, Duaa
AU  - Jamal, Maha
AU  - Alsieni, Mohammed
AU  - Burzangi, Abdulhadi S.
AU  - Zaher, M. A. F
AU  - Bendary, Mohammed
TI  - The protective effect of Astaxanthin on scopolamine - induced Alzheimer’s model in mice
AID  - 10.17712/nsj.2024.2.20230060
DP  - 2024 Apr 01
TA  - Neurosciences Journal
PG  - 103--112
VI  - 29
IP  - 2
4099  - http://nsj.org.sa/content/29/2/103.short
4100  - http://nsj.org.sa/content/29/2/103.full
SO  - Neurosciences (Riyadh)2024 Apr 01; 29
AB  - Objectives: To investigate the fundamental mechanisms of the neuroprotective impact of Astaxanthin (AST) in a mouse model of Alzheimer’s disease (AD) induced by scopolamine.Methods: This research constituted an in vivo animal study encompassing 36 adult male mice, divided into 6 groups: Control, 100 mg/kg AST, 2 mg/kg scopolamine (AD group), 100 mg/kg AST+2 mg/kg scopolamine, 3 mg/kg galantamine+2 mg/kg scopolamine, and 100 mg/kg AST+3 mg/kg galantamine+2 mg/kg scopolamine. After 14 days, the mice’s short-term memory, hippocampus tissue, oxidative and inflammatory markers were evaluated.Results: The AST demonstrated a beneficial influence on short-term memory and a reduction in acetylcholinesterase activity in the brain. It exhibited neuroprotective and anti-amyloidogenic properties, significantly decreased pro-inflammatory markers and oxidative stress, and reversed the decline of the Akt-1 and phosphorylated Akt pathway, a crucial regulator of abnormal tau. Furthermore, AST enhanced the effect of galantamine in reducing inflammation and oxidative stress.Conclusion: The findings indicate that AST may offer therapeutic benefits against cognitive dysfunction in AD. This is attributed to its ability to reduce oxidative stress, control neuroinflammation, and enhance Akt-1 and pAkt levels, thereby underscoring its potential in AD treatment strategies.